The Young Women's Breast Cancer Study (HOHO)
| Tracking Information | |||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| First Received Date ICMJE | November 5, 2011 | ||||||||||||||||||||||||||||||||
| Last Updated Date | September 11, 2012 | ||||||||||||||||||||||||||||||||
| Start Date ICMJE | November 2006 | ||||||||||||||||||||||||||||||||
| Estimated Primary Completion Date | November 2025 (final data collection date for primary outcome measure) | ||||||||||||||||||||||||||||||||
| Current Primary Outcome Measures ICMJE |
|
||||||||||||||||||||||||||||||||
| Original Primary Outcome Measures ICMJE | Same as current | ||||||||||||||||||||||||||||||||
| Change History | Complete list of historical versions of study NCT01468246 on ClinicalTrials.gov Archive Site | ||||||||||||||||||||||||||||||||
| Current Secondary Outcome Measures ICMJE |
Identify Predictors of Outcome [ Time Frame: 10 years ] [ Designated as safety issue: No ] Ultimately, the investigators aim to develop predictors of outcome and identify areas that may be amenable to intervention for young women with breast cancer. |
||||||||||||||||||||||||||||||||
| Original Secondary Outcome Measures ICMJE | Same as current | ||||||||||||||||||||||||||||||||
| Current Other Outcome Measures ICMJE | Not Provided | ||||||||||||||||||||||||||||||||
| Original Other Outcome Measures ICMJE | Not Provided | ||||||||||||||||||||||||||||||||
| Descriptive Information | |||||||||||||||||||||||||||||||||
| Brief Title ICMJE | The Young Women's Breast Cancer Study | ||||||||||||||||||||||||||||||||
| Official Title ICMJE | Helping Ourselves, Helping Others: The Young Women's Breast Cancer Study | ||||||||||||||||||||||||||||||||
| Brief Summary | The investigators are conducting a longitudinal cohort study of young women with breast cancer. The investigators identify women age 40 and younger with newly-diagnosed breast cancer from academic and community healthcare institutions. After women consent to the study, they fill-out surveys and give blood samples, and the investigators collect tissue from their breast cancer tumor after it is removed. Women are surveyed every 6 months for the first 3 years after diagnosis, then yearly thereafter for an additional 7 years (for a total follow-up of at least 10 years following diagnosis). The study investigates short and long-term disease and treatment issues, tumor biology and the relationship to patient outcomes, and psychosocial concerns at baseline and in follow-up among a cohort of young women who are newly-diagnosed with breast cancer. |
||||||||||||||||||||||||||||||||
| Detailed Description | This is a longitudinal cohort study of young women with breast cancer. Over a 6-year period, the investigators aim to identify over 1,300 women age 40 and younger with newly diagnosed breast cancer from academic and community health care institutions. It is anticipated that 1,000 of these women will agree to participate in an observational study. Patient surveys, medical record review, and blood and tissue collection will be utilized. Women will be surveyed every 6 months for the first 3 years after diagnosis, then yearly thereafter for an additional 7 years (for a total follow-up of 10 year following diagnosis). The study will investigate short and long-term disease and treatment issues, and psychosocial concerns at baseline and in follow-up among a cohort of young women (age 40 or younger) newly diagnosed with breast cancer. The investigators aim to characterize the population of young women at diagnosis and in follow-up regarding disease and psychosocial outcomes (e.g., presentation and disease characteristics, treatment patterns and quality of care, short and long-term side effects, and psychosocial concerns including fertility, sexual functioning, and menopausal issues). The investigators will also collect tumor and blood specimens to characterize the tumors, and bank for future studies including molecular evaluations of disease characteristics, genetic variability and hormonal levels in blood. Ultimately, the investigators aim to develop predictors of outcome, and identify areas that may be amenable to intervention. |
||||||||||||||||||||||||||||||||
| Study Type ICMJE | Observational | ||||||||||||||||||||||||||||||||
| Study Design ICMJE | Observational Model: Cohort Time Perspective: Prospective |
||||||||||||||||||||||||||||||||
| Target Follow-Up Duration | Not Provided | ||||||||||||||||||||||||||||||||
| Biospecimen | Retention: Samples With DNA Description: The investigators are collecting blood and tumor specimens. |
||||||||||||||||||||||||||||||||
| Sampling Method | Non-Probability Sample | ||||||||||||||||||||||||||||||||
| Study Population | This study includes women who are newly-diagnosed with breast cancer. They must be 40 or younger at their diagnosis. |
||||||||||||||||||||||||||||||||
| Condition ICMJE | Breast Cancer | ||||||||||||||||||||||||||||||||
| Intervention ICMJE | Not Provided | ||||||||||||||||||||||||||||||||
| Study Group/Cohort (s) | Young Women
Young women with newly diagnosed breast cancer |
||||||||||||||||||||||||||||||||
| Publications * | Not Provided | ||||||||||||||||||||||||||||||||
|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||||||||||||||||||||||||||||||
| Recruitment Information | |||||||||||||||||||||||||||||||||
| Recruitment Status ICMJE | Recruiting | ||||||||||||||||||||||||||||||||
| Estimated Enrollment ICMJE | 1000 | ||||||||||||||||||||||||||||||||
| Estimated Completion Date | January 2026 | ||||||||||||||||||||||||||||||||
| Estimated Primary Completion Date | November 2025 (final data collection date for primary outcome measure) | ||||||||||||||||||||||||||||||||
| Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
||||||||||||||||||||||||||||||||
| Gender | Female | ||||||||||||||||||||||||||||||||
| Ages | 18 Years to 40 Years | ||||||||||||||||||||||||||||||||
| Accepts Healthy Volunteers | No | ||||||||||||||||||||||||||||||||
| Contacts ICMJE |
|
||||||||||||||||||||||||||||||||
| Location Countries ICMJE | United States, Canada | ||||||||||||||||||||||||||||||||
| Administrative Information | |||||||||||||||||||||||||||||||||
| NCT Number ICMJE | NCT01468246 | ||||||||||||||||||||||||||||||||
| Other Study ID Numbers ICMJE | 06-169 | ||||||||||||||||||||||||||||||||
| Has Data Monitoring Committee | No | ||||||||||||||||||||||||||||||||
| Responsible Party | Ann H. Partridge, MD, MPH, Dana-Farber Cancer Institute | ||||||||||||||||||||||||||||||||
| Study Sponsor ICMJE | Dana-Farber Cancer Institute | ||||||||||||||||||||||||||||||||
| Collaborators ICMJE | Not Provided | ||||||||||||||||||||||||||||||||
| Investigators ICMJE |
|
||||||||||||||||||||||||||||||||
| Information Provided By | Dana-Farber Cancer Institute | ||||||||||||||||||||||||||||||||
| Verification Date | September 2012 | ||||||||||||||||||||||||||||||||
|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |
|||||||||||||||||||||||||||||||||